Unavailable
Unavailable
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 4/22/2024 | $30.00 | Buy | BofA Securities |
| 1/12/2024 | $24.00 → $15.00 | Outperform → Sector Perform | RBC Capital Mkts |
| 10/10/2023 | Outperform → Perform | Oppenheimer | |
| 8/28/2023 | $36.00 | Buy | UBS |
| 6/13/2023 | $49.00 | Outperform | Evercore ISI |
| 5/12/2022 | $33.00 → $12.00 | Outperform → Strong Buy | Raymond James |
| 12/20/2021 | $46.00 | Buy | HC Wainwright & Co. |
| 10/26/2021 | $58.00 → $49.00 | Overweight | Cantor Fitzgerald |
SC 13G/A - 89bio, Inc. (0001785173) (Subject)
SC 13G/A - 89bio, Inc. (0001785173) (Subject)
SC 13D/A - 89bio, Inc. (0001785173) (Subject)
4 - 89bio, Inc. (0001785173) (Issuer)
4 - 89bio, Inc. (0001785173) (Issuer)
4 - 89bio, Inc. (0001785173) (Issuer)
BofA Securities resumed coverage of 89bio with a rating of Buy and set a new price target of $30.00
RBC Capital Mkts downgraded 89bio from Outperform to Sector Perform and set a new price target of $15.00 from $24.00 previously
Oppenheimer downgraded 89bio from Outperform to Perform
Cantor Fitzgerald analyst Kristen Kluska reiterates 89bio (NASDAQ:ETNB) with a Overweight and maintains $29 price target.
Cantor Fitzgerald analyst Kristen Kluska reiterates 89bio (NASDAQ:ETNB) with a Overweight and maintains $29 price target.
Cantor Fitzgerald analyst Kristen Kluska reiterates 89bio (NASDAQ:ETNB) with a Overweight and maintains $29 price target.
4 - 89bio, Inc. (0001785173) (Issuer)
10-Q - 89bio, Inc. (0001785173) (Filer)
8-K/A - 89bio, Inc. (0001785173) (Filer)
8-K - 89bio, Inc. (0001785173) (Filer)
– The Phase 3 ENLIGHTEN program in patients with non-cirrhotic (F2-F3) and compensated cirrhotic (F4) metabolic dysfunction-associated steatohepatitis (MASH) continues to enroll patients across both trials – – Topline data from the Phase 3 ENTRUST trial in patients with severe hypertriglyceridemia (SHTG) are expected in 2025 – – Strengthened the Board of Directors and Executive Leadership Team with the appointments of Charles McWherter, Ph.D. to the Board of Directors, Francis Sarena as Chief Operating Officer, and Teresa Perney, Ph.D. as Chief Regulatory and Quality Officer – SAN FRANCISCO, Nov. 07, 2024 (GLOBE NEWSWIRE) -- 89bio, Inc. (NASDAQ:ETNB), a clinical-stage biopharmaceutical
SAN FRANCISCO, Nov. 05, 2024 (GLOBE NEWSWIRE) -- 89bio, Inc. (the "Company" or "89bio") (NASDAQ:ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, today announced that the Company's Management will participate in a fireside chat at the UBS Global Healthcare Conference on Tuesday, November 12, 2024 at 12:30 PM EST and participate in one-on-one investor meetings. The webcast of the presentation will be accessible in the investor section of 89bio's website. A replay of the webcast will be available for approximately 30 days following the conference. About 89bio89b
SAN FRANCISCO, Oct. 11, 2024 (GLOBE NEWSWIRE) -- 89bio, Inc. (the "Company" or "89bio") (NASDAQ:ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, today announced that the Compensation Committee of the Company's Board of Directors approved the grant of non-qualified stock options to purchase an aggregate of 265,000 shares of the Company's common stock to two new employees (the "Inducement Grants") on October 10, 2024 (the "Grant Date"). The Inducement Grants have been granted pursuant to the Company's 2023 Inducement Plan (the "Plan"). The Inducement Grants were
SAN FRANCISCO, Sept. 16, 2024 (GLOBE NEWSWIRE) -- 89bio, Inc. (NASDAQ:ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, announced the appointment of Teresa Perney, Ph.D. as Chief Regulatory and Quality Officer, effective today. Dr. Perney brings an extensive track record of expertise and leadership in Regulatory, Product Development and Quality in the industry to the Company. "We are delighted to welcome Dr. Teresa Perney to our executive leadership team at this critical juncture for 89bio," said Rohan Palekar, CEO of 89bio. "As we advance pegozafermin through
SAN FRANCISCO, Aug. 07, 2024 (GLOBE NEWSWIRE) -- 89bio, Inc. (NASDAQ:ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, today announced the appointment of Francis Sarena as Chief Operating Officer, effective August 5, 2024. "We are excited to welcome Francis to our executive team at this pivotal growth phase for 89bio," said Rohan Palekar, CEO of 89bio. "As we advance our Phase 3 clinical program for pegozafermin and prepare for scale up, Francis' extensive strategic, operational, business development and leadership expertise will be immensely valuable. His prov
SAN FRANCISCO, Aug. 05, 2024 (GLOBE NEWSWIRE) -- 89bio, Inc. (NASDAQ:ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, today announced the appointment of Dr. Charles McWherter to its Board of Directors, effective July 30, 2024. Dr. McWherter most recently served as Chief Scientific Officer and President of Research and Development of CymaBay Therapeutics until it was acquired by Gilead Sciences in March 2024. "We are thrilled to welcome Charles, an esteemed industry leader, to our Board of Directors," said Rohan Palekar, CEO of 89bio. "His expertise in drug dev
- 44mg Q2W dose had a placebo-adjusted effect size of 20% on at least one-stage fibrosis improvement without worsening of NASH (p=0.008) and 24% on NASH resolution without worsening of fibrosis (p=0.0005) - - 30mg QW dose had a placebo-adjusted effect size of 19% on at least one-stage fibrosis improvement without worsening of NASH (p=0.008) and 21% on NASH resolution without worsening of fibrosis (p=0.0009) - - 44mg Q2W and 30mg QW doses had at least one-stage fibrosis improvement without worsening of NASH at 3.5 times placebo rate and NASH resolution without worsening of fibrosis at 12 to 14 times placebo rate - - Every-two-week dose data reinforces pegozafermin's pot
- Trial met primary endpoint demonstrating statistically significant and clinically meaningful reductions across all doses (63% at the 27mg QW dose; p<0.001) in triglycerides (TG) from baseline; results were consistent in patients on or not on background therapy - - Observed significant and potent reductions in atherogenic lipids (non-HDL-C and apo B), liver fat, and improvements in liver enzymes and glycemic control markers - - ENTRIGUE results support 89bio's transition to a late-stage development company; Phase 3 expected to initiate in first half of 2023 - - Conference call and webcast today at 1:30 p.m. PST/4:30 p.m. EST - SAN FRANCISCO, June 28, 2022 (GLOBE NEWSWIRE) -- 89bio, In
- Interim data from NL-201 Phase 1 trial for patients with relapsed and refractory solid tumors anticipated in the second half of 2022 – - $142.5 million in cash and cash equivalents expected to provide runway into the second half of 2023 – - Appointment of Rohan Palekar to Board of Directors – - Company to host conference call today, March 1, 2022 at 1:30 p.m. PT / 4:30 p.m. ET – SEATTLE, March 01, 2022 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc., "Neoleukin" (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today announced financial results and a corporate update for the year ended December 31, 2021.